Yadagiri Jonna, MD
Internal Medicine · Bluffton, INNPI 1083655427
Payments from drug & device makers
Across 305 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$791
- AbbVie$627
- Bayer$448
- Lilly USA, LLC$440
- Novo Nordisk$438
- Medtronic$261
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,249100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $791 |
| AbbVie | 40 | $627 |
| Bayer | 30 | $448 |
| Lilly USA, LLC | 25 | $440 |
| Novo Nordisk | 33 | $438 |
| Medtronic | 3 | $261 |
| GSK | 14 | $212 |
| Boehringer Ingelheim | 11 | $197 |
| Otsuka America Pharmaceutical, Inc. | 8 | $153 |
| Johnson & Johnson | 8 | $144 |
| Pfizer | 8 | $126 |
| Novartis | 7 | $125 |
| Exact Sciences | 7 | $118 |
| Lundbeck LLC | 5 | $108 |
| Amgen | 5 | $105 |
| Sumitomo Pharma America, Inc. | 5 | $105 |
| Merck | 7 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Sanofi-aventis U.S. LLC | 6 | $98 |
| Sunovion Pharmaceuticals Inc. | 7 | $87 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 3 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Verona Pharma, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,261 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $160,088 |
| EliquisApixaban | 143 | $148,439 |
| XareltoRivaroxaban | 123 | $104,328 |
| FarxigaDapagliflozin Propanediol | 118 | $86,627 |
| JanuviaSitagliptin Phosphate | 76 | $83,209 |
| JardianceEmpagliflozin | 61 | $75,910 |
| TradjentaLinagliptin | 61 | $45,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $41,274 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $36,390 |
| LinzessLinaclotide | 44 | $33,866 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $32,332 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $31,929 |
| VraylarCariprazine Hcl | 19 | $30,856 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $27,138 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $24,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $438 | $166,786136 claims |
| PfizerEliquis | $126 | $148,439143 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $197 | $127,634133 claims |
| MerckJanuvia, Janumet, Belsomra | $104 | $121,991117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $212 | $105,535155 claims |
| Johnson & JohnsonXarelto | $144 | $104,328123 claims |
| AstraZenecaFarxiga | $791 | $86,627118 claims |
| AbbVieLinzess, Vraylar | $627 | $64,72263 claims |
| Lilly USA, LLCMounjaro | $440 | $14,44414 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $11,54417 claims |
| NovartisEntresto | $125 | $8,57413 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $105 | $4,84620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Bluffton
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.